Disease | N. SNPs d | DSI v | DPI v | Chr | Position | Consequence | Alleles | Class | AFEXOME | AFGENOME | Score vda | EI vda | N. PMIDs | First Ref. | Last Ref. | ||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Breast Carcinoma
|
2793 | 0.708 | 0.360 | 1 | 204549714 | 3 prime UTR variant | C/A;G | snv | 0.77; 6.2E-06 | 0.730 | 0.800 | 5 | 2013 | 2018 | |||||
Malignant neoplasm of breast
|
3417 | 0.708 | 0.360 | 1 | 204549714 | 3 prime UTR variant | C/A;G | snv | 0.77; 6.2E-06 | 0.730 | 0.750 | 4 | 2013 | 2018 | |||||
Malignant Neoplasms
|
1641 | 0.708 | 0.360 | 1 | 204549714 | 3 prime UTR variant | C/A;G | snv | 0.77; 6.2E-06 | 0.040 | 1.000 | 4 | 2013 | 2016 | |||||
Primary malignant neoplasm
|
1374 | 0.708 | 0.360 | 1 | 204549714 | 3 prime UTR variant | C/A;G | snv | 0.77; 6.2E-06 | 0.040 | 1.000 | 4 | 2013 | 2016 | |||||
Prostate carcinoma
|
1168 | 0.708 | 0.360 | 1 | 204549714 | 3 prime UTR variant | C/A;G | snv | 0.77; 6.2E-06 | 0.720 | 1.000 | 4 | 2013 | 2018 | |||||
Malignant neoplasm of prostate
|
1082 | 0.708 | 0.360 | 1 | 204549714 | 3 prime UTR variant | C/A;G | snv | 0.77; 6.2E-06 | 0.720 | 1.000 | 3 | 2013 | 2015 | |||||
Diastolic blood pressure
|
1037 | 0.708 | 0.360 | 1 | 204549714 | 3 prime UTR variant | C/A;G | snv | 0.77; 6.2E-06 | 0.700 | 1.000 | 2 | 2016 | 2018 | |||||
Adult Non-Hodgkin Lymphoma
|
39 | 0.708 | 0.360 | 1 | 204549714 | 3 prime UTR variant | C/A;G | snv | 0.77; 6.2E-06 | 0.010 | 1.000 | 1 | 2014 | 2014 | |||||
Childhood Non-Hodgkin Lymphoma
|
39 | 0.708 | 0.360 | 1 | 204549714 | 3 prime UTR variant | C/A;G | snv | 0.77; 6.2E-06 | 0.010 | 1.000 | 1 | 2014 | 2014 | |||||
Endometrial Carcinoma
|
326 | 0.708 | 0.360 | 1 | 204549714 | 3 prime UTR variant | C/A;G | snv | 0.77; 6.2E-06 | 0.010 | 1.000 | 1 | 2016 | 2016 | |||||
estrogen receptor-negative breast cancer
|
40 | 0.708 | 0.360 | 1 | 204549714 | 3 prime UTR variant | C/A;G | snv | 0.77; 6.2E-06 | 0.010 | 1.000 | 1 | 2017 | 2017 | |||||
Lymphoma, Non-Hodgkin
|
197 | 0.708 | 0.360 | 1 | 204549714 | 3 prime UTR variant | C/A;G | snv | 0.77; 6.2E-06 | 0.010 | 1.000 | 1 | 2014 | 2014 | |||||
Lymphoma, Non-Hodgkin, Familial
|
79 | 0.708 | 0.360 | 1 | 204549714 | 3 prime UTR variant | C/A;G | snv | 0.77; 6.2E-06 | 0.010 | 1.000 | 1 | 2014 | 2014 | |||||
Malignant neoplasm of endometrium
|
197 | 0.708 | 0.360 | 1 | 204549714 | 3 prime UTR variant | C/A;G | snv | 0.77; 6.2E-06 | 0.010 | 1.000 | 1 | 2016 | 2016 | |||||
Malignant neoplasm of stomach
|
615 | 0.708 | 0.360 | 1 | 204549714 | 3 prime UTR variant | C/A;G | snv | 0.77; 6.2E-06 | 0.010 | 1.000 | 1 | 2017 | 2017 | |||||
Malignant transformation
|
20 | 0.708 | 0.360 | 1 | 204549714 | 3 prime UTR variant | C/A;G | snv | 0.77; 6.2E-06 | 0.010 | 1.000 | 1 | 2013 | 2013 | |||||
Neoplasms
|
1644 | 0.708 | 0.360 | 1 | 204549714 | 3 prime UTR variant | C/A;G | snv | 0.77; 6.2E-06 | 0.010 | 1.000 | 1 | 2019 | 2019 | |||||
Squamous cell carcinoma of esophagus
|
329 | 0.708 | 0.360 | 1 | 204549714 | 3 prime UTR variant | C/A;G | snv | 0.77; 6.2E-06 | 0.010 | 1.000 | 1 | 2013 | 2013 | |||||
Squamous cell carcinoma of oropharynx
|
33 | 0.708 | 0.360 | 1 | 204549714 | 3 prime UTR variant | C/A;G | snv | 0.77; 6.2E-06 | 0.010 | 1.000 | 1 | 2019 | 2019 | |||||
Stomach Carcinoma
|
652 | 0.708 | 0.360 | 1 | 204549714 | 3 prime UTR variant | C/A;G | snv | 0.77; 6.2E-06 | 0.010 | 1.000 | 1 | 2017 | 2017 | |||||
Systolic Pressure
|
1931 | 0.708 | 0.360 | 1 | 204549714 | 3 prime UTR variant | C/A;G | snv | 0.77; 6.2E-06 | 0.700 | 1.000 | 1 | 2016 | 2016 |